| Literature DB >> 26697163 |
Daria Prilutsky1, Alvin T Kho2, Nathan P Palmer1, Asha L Bhakar3, Niklas Smedemark-Margulies4, Sek Won Kong5, David M Margulies6, Mark F Bear3, Isaac S Kohane7.
Abstract
BACKGROUND: Fragile X syndrome (FXS) is a neurodevelopmental disorder whose biochemical manifestations involve dysregulation of mGluR5-dependent pathways, which are widely modeled using cultured neurons. In vitro phenotypes in cultured neurons using standard morphological, functional, and chemical approaches have demonstrated considerable variability. Here, we study transcriptomes obtained in situ in the intact brain tissues of a murine model of FXS to see how they reflect the in vitro state.Entities:
Keywords: Brain; Fragile X syndrome; Gene expression; Murine model; Neuronal cultures
Year: 2015 PMID: 26697163 PMCID: PMC4687343 DOI: 10.1186/s13229-015-0061-9
Source DB: PubMed Journal: Mol Autism Impact factor: 7.509
Fig. 1Principal component analysis (PCA) of global transcriptional profiles in murine Fmr1KO/WT culture and brain tissues. PCA captures the differences between primary tissue or culture type and region of the brain as identified by expression levels of 45,101 probes in 42 samples. The scatter indicates that gene expression profiles of cortical and hippocampal neuronal cultures captured the difference between genotypes
Enriched pathways in differentially expressed genes in brain and primary cultures of Fmr1KO mice
| KEGG pathway (ENTREZ ID as input) |
| No. of genes | Fold enrichment |
|---|---|---|---|
| Hippocampal culture | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| mmu00790:Folate biosynthesis | 0.070 | 5 | 3.019 |
| mmu04914:Progesterone-mediated oocyte maturation | 0.078 | 19 | 1.485 |
| mmu04150:mTOR signaling pathway | 0.080 | 13 | 1.661 |
| mmu00240:Pyrimidine metabolism | 0.088 | 20 | 1.444 |
| mmu05220:Chronic myeloid leukemia | 0.088 | 17 | 1.506 |
| Cortical culture | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| mmu04720:Long-term potentiation | 0.052 | 19 | 1.548 |
| mmu00534:Heparan sulfate biosynthesis | 0.062 | 9 | 2.016 |
| mmu03450:Non-homologous end-joining | 0.076 | 6 | 2.481 |
| mmu04062:Chemokine signaling pathway | 0.080 | 41 | 1.267 |
| mmu05210:Colorectal cancer | 0.096 | 22 | 1.391 |
| Hippocampus in situ | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6 |
|
| mmu05330:Allograft rejection | 0.051 | 5 | 3.523 |
| mmu04672:Intestinal immune network for IgA production | 0.082 | 5 | 2.998 |
| mmu04610:Complement and coagulation cascades | 0.099 | 6 | 2.415 |
| Cortex in situ | |||
|
|
|
|
|
|
|
|
|
|
| mmu04640:Hematopoietic cell lineage | 0.059 | 8 | 2.275 |
| mmu04060:Cytokine-cytokine receptor interaction | 0.064 | 16 | 1.623 |
| mmu00601:Glycosphingolipid biosynthesis | 0.083 | 4 | 3.838 |
Italics highlight pathways with p values <0.05
Fig. 2Integration of human GSE25219 and mouse data with cluster-representative profiles. The maps show gene-centric PCA (left panel) of 15 human developmental stages in hippocampus (top) and in cortex (bottom). Median profile for each cluster is represented on the right panel of the figure
Fig. 3Differentially expressed murine genes highlighted on the human developmental transcriptome map. Differentially expressed genes in Fmr1KO a hippocampal and b cortical culture are expressed early in human development and expressed late in c in situ hippocampus and d in situ cortex (blue: down-regulated, red: up-regulated, black: combined)
Integration of human neocortex/hippocampus developmental genes and mouse differentially expressed genes in culture and brain
| Case/cluster | H0 | H1 | H2 | Case/cluster | C0 | C1 | C2 |
|---|---|---|---|---|---|---|---|
| All genes | 5808 | 4242 | 3780 | All genes | 5572 | 4217 | 4041 |
| % | 42 | 31 | 27 | % | 40 | 30 | 29 |
| Differentially expressed genes in cultured cells | |||||||
| Hippo culture KO/WT down | 239 | 200 | 260 | Cortex culture KO/WT down | 428 | 461 | 408 |
| % | 34 | 29 | 37 | % | 33 | 36 | 31 |
| Hippo culture KO/WT up | 821 | 191 | 298 | Cortex culture KO/WT up | 732 | 268 | 168 |
| % | 63 | 15 | 23 | % | 63 | 23 | 14 |
| Hippo culture KO/WT combined | 1060 | 391 | 558 | Cortex culture KO/WT combined | 1160 | 729 | 576 |
| % | 53 | 19 | 28 | % | 47 | 30 | 23 |
| Differentially expressed genes in primary brain tissue | |||||||
| Hippo brain KO/WT down | 92 | 126 | 65 | Cortex brain KO/WT down | 102 | 52 | 57 |
| % | 32.5 | 44.5 | 23 | % | 48.3 | 24.6 | 27.1 |
| Hippo brain KO/WT up | 61 | 71 | 39 | Cortex brain KO/WT up | 96 | 81 | 162 |
| % | 35.7 | 41.5 | 22.8 | % | 28.3 | 24 | 47.7 |
| Hippo brain KO/WT combined | 153 | 197 | 104 | Cortex brain KO/WT combined | 198 | 133 | 219 |
| % | 33.7 | 43.4 | 22.9 | % | 36 | 24.2 | 39.8 |
Summary of findings
| Differentially expressed genes in | ||||
|---|---|---|---|---|
| Culture | Brain | |||
| Hippocampus | Cortex | Hippocampus | Cortex | |
| Number of differentially expressed genes | 2648 | 3372 | 726 | 866 |
| Distance between KO and WT clusters on PCA (PC1/PC2) | 3.73/0.7 | 3.31/3.20 | 0.99/0.6 | 0.39/0.32 |
| Pathway enrichment | Neuronal processes | Immune processes | ||
| Human development | Early (H0 cluster) | Early (C0 cluster) | Later (H1 cluster) | Later (C2 cluster) |
| Up-regulated | Up-regulated | Down- and up- regulated | Up-regulated | |
| SFARI human genes | Significantly enriched in down-regulated genes | Significantly enriched in down-regulated genes | Not significant | Not significant |
| MGI mouse genes associated with behavioral/neurological phenotype | Significantly enriched in down-regulated genes | Significantly enriched in down-regulated genes | Not significant | Not significant |
| FMRP targets | Significantly enriched in down-regulated genes | Significantly enriched in down- and up- regulated genes | Not significant | Not significant |